100 related articles for article (PubMed ID: 15599929)
41. [Contribution of Japanese researchers to progress in the study of allergy and collagen disease in the last 100 years: Fas and autoimmune diseases].
Eguchi K
Nihon Naika Gakkai Zasshi; 2002 Sep; 91(9):2599-603. PubMed ID: 12373878
[No Abstract] [Full Text] [Related]
42. Immune privilege or inflammation? Insights into the Fas ligand enigma.
O'Connell J; Houston A; Bennett MW; O'Sullivan GC; Shanahan F
Nat Med; 2001 Mar; 7(3):271-4. PubMed ID: 11231613
[TBL] [Abstract][Full Text] [Related]
43. Gene therapy for tolerance and autoimmunity: soon to be fulfilled promises?
El-Amine M; Melo ME; Scott DW
Clin Immunol; 2001 Apr; 99(1):1-6. PubMed ID: 11286536
[No Abstract] [Full Text] [Related]
44. Role of Fas/FasL interaction in physiology and pathology: the good and the bad.
Sakata K; Sakata A; Kong L; Dang H; Talal N
Clin Immunol Immunopathol; 1998 Apr; 87(1):1-7. PubMed ID: 9576004
[No Abstract] [Full Text] [Related]
45. FasL, leukocytes and vascular modeling.
Ferguson TA; Stuart PM
Nat Med; 2004 Jan; 10(1):12; author reply 13. PubMed ID: 14702618
[No Abstract] [Full Text] [Related]
46. Immunology and immunopathology of male genital tract. Preface.
Lenzi A
Hum Reprod Update; 2001; 7(5):443. PubMed ID: 11556489
[No Abstract] [Full Text] [Related]
47. Inhibition of neutrophil activity in cardiac surgery with cardiopulmonary bypass: a novel strategy with the leukocyte inhibition module.
Moreno JB; Margraf S; Schuller AM; Simon A; Moritz A; Scholz M
Perfusion; 2004 Jan; 19(1):11-6. PubMed ID: 15072250
[TBL] [Abstract][Full Text] [Related]
48. First efficacy and safety results with the antibody containing leukocyte inhibition module in cardiac surgery patients with neutrophil hyperactivity.
Scholz M; Cinatl J; Barros RT; Lisboa AC; Genevcius CF; Margraf S; Francischetti I; Oremek G; Windolf J; Simon A; Moritz A; Bitu-Moreno J
ASAIO J; 2005; 51(2):144-7. PubMed ID: 15839438
[TBL] [Abstract][Full Text] [Related]
49. Countering the 'counterattack' hypothesis.
Restifo NP
Nat Med; 2001 Mar; 7(3):259. PubMed ID: 11231598
[No Abstract] [Full Text] [Related]
50. The Role of Caspase Family in Acute Brain Injury: The Potential Therapeutic Targets in the Future.
Zhang A; Zhang Z; Liu Y; Lenahan C; Xu H; Jiang J; Yuan L; Wang L; Xu Y; Chen S; Fang Y; Zhang J
Curr Neuropharmacol; 2022; 20(6):1194-1211. PubMed ID: 34766893
[TBL] [Abstract][Full Text] [Related]
51. ULK1 affects cell viability of goat Sertoli cell by modulating both autophagy and apoptosis.
Pang J; Han L; Liu Z; Zheng J; Zhao J; Deng K; Wang F; Zhang Y
In Vitro Cell Dev Biol Anim; 2019 Sep; 55(8):604-613. PubMed ID: 31359348
[TBL] [Abstract][Full Text] [Related]
52. Apoptosis and Compensatory Proliferation Signaling Are Coupled by CrkI-Containing Microvesicles.
Gupta KH; Goldufsky JW; Wood SJ; Tardi NJ; Moorthy GS; Gilbert DZ; Zayas JP; Hahm E; Altintas MM; Reiser J; Shafikhani SH
Dev Cell; 2017 Jun; 41(6):674-684.e5. PubMed ID: 28633020
[TBL] [Abstract][Full Text] [Related]
53. Subtype-Specific Radiation Response and Therapeutic Effect of FAS Death Receptor Modulation in Human Breast Cancer.
Lee CT; Zhou Y; Roy-Choudhury K; Siamakpour-Reihani S; Young K; Hoang P; Kirkpatrick JP; Chi JT; Dewhirst MW; Horton JK
Radiat Res; 2017 Aug; 188(2):169-180. PubMed ID: 28598289
[TBL] [Abstract][Full Text] [Related]
54. Association between Fas/FasL polymorphism and susceptibility to leukemia: a meta-analysis.
Chen Y; He Y; Lu X; Zeng Z; Tang C; Xue T; Li Y
Int J Clin Exp Med; 2015; 8(3):3817-24. PubMed ID: 26064279
[TBL] [Abstract][Full Text] [Related]
55. A comparison of the effects of estrogen and Cimicifuga racemosa on the lacrimal gland and submandibular gland in ovariectomized rats.
Da Y; Niu K; Wang K; Cui G; Wang W; Jin B; Sun Y; Jia J; Qin L; Bai W
PLoS One; 2015; 10(3):e0121470. PubMed ID: 25793872
[TBL] [Abstract][Full Text] [Related]
56. Clinical implications of Fas/Fas ligand expression in patients with esophageal squamous cell carcinoma following neoadjuvant chemoradiotherapy.
Saigusa S; Tanaka K; Ohi M; Toiyama Y; Yasuda H; Kitajima T; Okugawa Y; Inoue Y; Mohri Y; Kusunoki M
Mol Clin Oncol; 2015 Jan; 3(1):151-156. PubMed ID: 25469286
[TBL] [Abstract][Full Text] [Related]
57. FOXL2 suppresses proliferation, invasion and promotes apoptosis of cervical cancer cells.
Liu XL; Meng YH; Wang JL; Yang BB; Zhang F; Tang SJ
Int J Clin Exp Pathol; 2014; 7(4):1534-43. PubMed ID: 24817949
[TBL] [Abstract][Full Text] [Related]
58. Activated cytotoxic lymphocytes promote tumor progression by increasing the ability of 3LL tumor cells to mediate MDSC chemoattraction via Fas signaling.
Yang F; Wei Y; Cai Z; Yu L; Jiang L; Zhang C; Yan H; Wang Q; Cao X; Liang T; Wang J
Cell Mol Immunol; 2015 Jan; 12(1):66-76. PubMed ID: 24769795
[TBL] [Abstract][Full Text] [Related]
59. Associations between Fas/FasL polymorphisms and susceptibility to cervical cancer: a meta-analysis.
Wang GQ; Bao L; Zhao XX; Zhang J; Nan KJ
Tumour Biol; 2014 May; 35(5):4107-12. PubMed ID: 24375196
[TBL] [Abstract][Full Text] [Related]
60. Targeting Fas in osteoresorptive disorders.
Kovacic N; Grcevic D; Katavic V; Lukic IK; Marusic A
Expert Opin Ther Targets; 2010 Oct; 14(10):1121-34. PubMed ID: 20854180
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
